DUBLIN, Dec. 22, 2021 /PRNewswire/ — The "Hematology Testing Market – Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Hematology Testing Market Report
The hematology testing market size was valued at USD 3,384.34 million in 2021 and is expected to reach USD 4,409.22 million by 2027, growing at a CAGR of 4.51% during the forecast period
Market Overview
The growth of the market can be attributed to the high prevalence/incidence of several acute, chronic, and infectious diseases, especially blood-related ailments. An increased number of programmed parameters in the hematology analyzers have increased their scope of usage in various new health condition diagnostics. The conventional methods are very expensive for the rare blood-related disorders in the market. There is a huge scope for hematology testing in the new disease conditions.
The following factors are likely to contribute to the growth of the hematology testing market –
Artificial Intelligence in Hematology Testing
Increase in Demand for Point of Care Hematology Testing
Technological Advancements in Hematology Testing
Increased Adoption of Telehealth
Increasing Product Launches
Integration of Flow-Cytometry with Hematology Analysers
Increasing Blood Transfusions & Donations
Key Highlights
At least once in a lifetime, 70% of the population will undergo the CBC test. The scope of CDC is increasing for various new diagnostics. This will drive the market largely.
Due to the shortage of physicians and other benefits through the telehealth platforms, the hospitals are largely adopting telehealth. This scenario has a major impact on the hematology market. The doctors prescribe the tests, the patients are preferring to undergo tests in the nearby smaller diagnostic labs or physician offices and share the results in the telehealth platform.
Key Questions Answered:
1. What is the size of the hematology testing market?
2. What are the latest trends in the global hematology diagnostic market?
3. Which region has the highest share in the hematology testing market?
4. Who are the end-users in the hematology testing market?
5. Who are the key players in the hematology testing market?
Key Topics Covered:
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope Of The Study
4.3.1 Market Segment By Product
4.3.2 Market Segment By Test Type
4.3.3 Market Segment By End-User
4.3.4 Market Segmentation By Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market At A Glance
7 Introduction
7.1 Overview
7.2 Impact Of Covid-19 On Hematology Testing
7.2.1 Covid-19 An Opportunity For Hematology Testing
8 Market Opportunities & Trends
8.1 Artificial Intelligence In Hematology Testing
8.2 Increase In Demand For Point-Of-Care Hematology Testing
8.3 Technological Advancements In Hematology Testing
8.4 Increased Adoption Of Telehealth
9 Market Growth Enablers
9.1 Increasing Product Launches
9.2 Integration Of Flow Cytometry With Hematology Analyzers
9.3 Increasing Blood Transfusions & Donations
10 Market Restraints
10.1 Stringent Regulations Coupled With Product Recalls & Safety Concerns
10.2 High Initial Investment & Maintenance Of Hematology Analyzers
10.3 Lower-Than-Expected Penetration Of Advanced Hematology Analyzers In LMICS
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat Of New Entrants
11.3.2 Bargaining Power Of Suppliers
11.3.3 Bargaining Power Of Buyers
11.3.4 Threat Of Substitutes
11.3.5 Competitive Rivalry
12 Product
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Consumables
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Consumables – Geography Segmentation
12.4 Analyzers
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Analyzers – Geography Segmentation
13 Analyzers – Part Differential
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 5&6-Part
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 5&6-Part Hematology Analyzers – Geography Segmentation
13.4 3-PART
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 3-Part Hematology Analyzers – Geography Segmentation
14 Analyzers – Volume
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Small & Medium Volume
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Small & Medium Volume – Geography Segmentation
14.4 High Volume
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 High Volume – Geography Segmentation
15 Test
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Routine Tests
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Routine Tests – Geography Segmentation
15.4 Specialty Tests
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Specialty Tests – Geography Segmentation
16 End-User
16.1 Market Snapshot & Growth Engine
16.2 Market Overview
16.3 Hospitals
16.3.1 Market Overview
16.3.2 Market Size & Forecast
16.3.3 Hospitals – Geography Segmentation
16.4 Standard Reference Laboratories
16.4.1 Market Overview
16.4.2 Market Size & Forecast
16.4.3 Standard Reference Laboratories – Geography Segmentation
16.5 Blood Bank
16.5.1 Market Overview
16.5.2 Market Size & Forecast
16.5.3 Blood Banks – Geography Segmentation
16.6 Others
16.6.1 Market Overview
16.6.2 Market Size & Forecast
16.6.3 Others – Geography Segmentation
17 Geography
17.1 Market Snapshot & Growth Engine
17.2 Geographic Overview
18 North America
19 Europe
20 APAC
21 Latin America
22 Middle East & Africa
23 Competitive Landscape
23.1 Competition Overview
23.2 Market Share Analysis
23.2.1 Abbott
23.2.2 Boule Diagnostics
23.2.3 Danaher
23.2.4 Diatron
23.2.5 HORIBA
23.2.6 NIHON KOHDEN
23.2.7 SHENZEN MINDRAY BIO-MEDICAL ELECTRONICS
23.2.8 Siemens Healthineers
23.2.9 Sysmex
24 Key Company Profiles
24.1 ABBOTT
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 BOULE DIAGNOSTICS
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 DANAHER
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 DIATRON
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 HORIBA
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunities
24.6 NIHON KOHDEN
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities
24.8 SIEMENS HEALTHINEERS
24.8.1 Business Overview
24.8.2 Product Offerings
24.8.3 Key Strategies
24.8.4 Key Strengths
24.8.5 Key Opportunities
24.9 SYSMEX
24.9.1 Business Overview
24.9.2 Product Offerings
24.9.3 Key Strategies
24.9.4 Key Strengths
24.9.5 Key Opportunities
25 Other Prominent Vendors
25.1 ALPHA SCIENTIFIC
25.1.1 Business Overview
25.1.2 Product Offerings
25.2 AGAPPE DIAGNOSTICS
25.2.1 Business Overview
25.2.2 Product Offerings
25.3 ANALYTICON BIOTECHNOLOGIES
25.3.1 Business Overview
25.3.2 Product Offerings
25.4 BALIO DIAGNOSTICS
25.4.1 Business Overview
25.4.2 Product Offerings
25.5 B&E BIO-TECHNOLOGY
25.5.1 Business Overview
25.5.2 Product Offerings
25.6 BIOSYSTEMS
25.6.1 Business Overview
25.6.2 Product Offerings
25.7 BIOWAY BIOLOGICAL TECHNOLOGY
25.7.1 Business Overview
25.7.2 Product Offerings
25.8 BIO-RAD
25.8.1 Business Overview
25.8.2 Product Offerings
25.9 CLINDIAG SYSTEMS
25.9.1 Business Overview
25.9.2 Product Offerings
25.10 CONTECH MEDICAL SYSTEMS
25.10.1 Business Overview
25.10.2 Product Offerings
25.11 CONVERGENT TECHNOLOGIES
25.11.1 Business Overview
25.11.2 Product Offerings
25.12 CPC DIAGNOSTICS
25.12.1 Business Overview
25.12.2 Product Offerings
25.13 CPM SCIENTIFICA
25.13.1 Business Overview
25.13.2 Product Offerings
25.14 DIAGON
25.14.1 Business Overview
25.14.2 Product Offerings
25.15 DIRUI
25.15.1 Business Overview
25.15.2 Product Offerings
25.16 DRUCKER DIAGNOSTICS
25.16.1 Business Overview
25.16.2 Product Offerings
25.17 ERBA DIAGNOSTICS
25.17.1 Business Overview
25.17.2 Product Offerings
25.18 EDAN INSTRUMENTS
25.18.1 Business Overview
25.18.2 Product Offerings
25.19 F. HOFFMANN-LA ROCHE
25.19.1 Business Overview
25.19.2 Product Offerings
25.20 GENRUI BIOTECH
25.20.1 Business Overview
25.20.2 Product Offerings
25.21 HIGH TECHNOLOGY
25.21.1 Business Overview
25.21.2 Product Offerings
25.22 SHENZHEN LANDWIND MEDICAL
25.22.1 Business Overview
25.22.2 Product Offerings
25.23 LINEAR CHEMICALS
25.23.1 Business Overview
25.23.2 Product Offerings
25.24 MACCURA BIOTECHNOLOGY
25.24.1 Business Overview
25.24.2 Product Offerings
25.25 MERIL LIFESCIENCES
25.25.1 Business Overview
25.25.2 Product Offerings
25.26 NORMA
25.26.1 Business Overview
25.26.2 Product Offerings
25.27 PRESTIGE DIAGNOSTICS
25.27.1 Business Overview
25.27.2 Product Offerings
25.28 SFRI
25.28.1 Business Overview
25.28.2 Product Offerings
25.29 SHENZHEN DYMIND BIOTECHNOLOGY
25.29.1 Business Overview
25.29.2 Product Offerings
25.30 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY
25.30.1 Business Overview
25.30.2 Product Offerings
25.31 SHENZHEN PROKAN ELECTRONICS
25.31.1 Business Overview
25.31.2 Product Offerings
25.32 SPINREACT
25.32.1 Business Overview
25.32.2 Product Offerings
25.33 TRIVITRON HEALTHCARE
25.33.1 Business Overview
25.33.2 Product Offerings
26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations
27 Quantitative Summary
28 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/ctg1on
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-hematology-testing-market-2021-to-2027—featuring-abbott-boule-diagnostics-and-diatron-among-others-301449896.html
SOURCE Research and Markets
(Bloomberg) — Intel Corp. apologized after its opposition to Xinjiang labor sparked a backlash against the U.S. chipmaker in China, highlighting how multinational companies are increasingly getting caught up in a geopolitical spat between two global powers over issues such as human rights. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two St
See: I’m a 35-year-old father of four with $135,000 saved for retirement. Retirement can be an emotional time, usually for individuals leaving the workforce who have felt their careers defined much of who they are, but sometimes also for the retiring person’s family. Your wife may have a lot of feelings associated with your retirement, and it’s important to keep her in the loop every step of the way, as you seem to have done so far.
Dr. Owais Durrani, an emergency medicine physician, joins Yahoo Finance to discuss what Pfizer’s COVID-19 pill and Biden’s winter plan to address rising Omicron cases means in the fight against the coronavirus.
Whether GE ultimately continues as one company or three, it needs to stop offshoring manufacturing jobs.
Mining profitability levels for bitcoin are finally on the decline, according to a new report. And months of declining profitability may follow.
(Bloomberg) — Tesla Inc. has agreed to take the majority of battery-ready graphite from a production facility planned in Louisiana, as it races to secure supplies of the key material in a market dominated by China. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retirement HotspotBid
Some retirement advisors are cautioning that the famous 4% Rule no longer works. But the inventor of the 4% Rule says you can actually withdraw 4.7%.
Global oil demand roared back in 2021 as the world began to recover from the coronavirus pandemic, and overall world consumption potentially could hit a new record in 2022 – despite efforts to bring down fossil fuel consumption to mitigate climate change. For 2022, crude consumption is expected to reach 99.53 million barrels per day (bpd), up from 96.2 million bpd this year, according to the International Energy Agency. Numerous OPEC nations have struggled to add to output, while the U.S. shale industry has to deal with investor demands to hold the line on spending.
These are the natural gas stocks with the best value, fastest growth, and most momentum for Q1 2022.
Fidelity Investments reported that the number of 401(k) millionaires—investors with 401(k) account balances of $1 million or more—reached 233,000 at the end of the fourth quarter of 2019, a 16% increase from the third quarter's count of 200,000 and up over 1000% from 2009's count of 21,000. Target-date funds are often offered as a default option by plan sponsors when employees don't make an investment choice on their own.
These are the utilities stocks with the best value, fastest growth, and most momentum for January 2022.
"Omi-whatever" sure didn’t last long.
The Russell 1000 Index is a market-capitalization-weighted index of the 1,000 largest publicly traded companies in the U.S. It represents approximately 92% of the total market capitalization of all listed stocks in the U.S. equity market. Value investing is a factor-based investing strategy that involves picking stocks that you believe are trading for less than what they are intrinsically worth, usually by measuring the ratio of the stock's price to one or more fundamental business metrics. Value investors believe that if a business is cheap compared to its intrinsic value, (as measured by its P/E ratio, in this case) the stock price may rise faster than that of others as the price comes back in line with the worth of the company.
The number of people leaving the workforce to become semi-retired, instead of fully retired, is growing. Here is a look at the reasons and options.
The administration has been calling for more output to rein in gasoline prices, but producers say its climate-change focus is a brake on more drilling.
(Bloomberg) — Intel Corp. is facing criticism in China after it asked suppliers not to use Xinjiang labor or products, threatening to ensnare the U.S. chipmaker in a dispute over human rights in the far western Chinese region. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retiremen
Workplace stress is rampant and resignations have risen. Employers are struggling to stop employees from leaving and to boost morale. Some are trying four-day workweeks, mandatory vacation days and other new ways of working.
After a blowout year, finance executives plan to go on rewarding their shareholders, and see little chance of a slower economy or a tax rise denting the momentum.
(Bloomberg) — China Telecom (Americas) Corp. said it intends to continue most of its U.S. operations despite an order from regulators to stop due to espionage concerns.Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retirement HotspotBiden Extends Student-Loan Payment Pause After Vir
Industry regulator Finra alleged the firm failed to detect transfers of client funds to two brokers’ own accounts.
